United Therapeutics (NASDAQ:UTHR) CEO Sells $5,386,880.00 in Stock

by · The Cerbat Gem

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $567.04, for a total value of $5,386,880.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,972,491.52. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Down 0.0%

NASDAQ UTHR traded down $0.19 on Tuesday, reaching $566.80. 402,311 shares of the stock traded hands, compared to its average volume of 477,982. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The firm’s fifty day simple moving average is $559.71 and its 200 day simple moving average is $508.76. The company has a market cap of $24.06 billion, a price-to-earnings ratio of 20.92, a P/E/G ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the company posted $6.63 EPS. As a group, equities research analysts forecast that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. TD Cowen increased their price objective on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America increased their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $619.42.

Get Our Latest Stock Report on UTHR

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC bought a new position in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC raised its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Featured Stories